论文部分内容阅读
细胞毒药物治疗是用于急性髓细胞性白血病(AML)治疗的主要手段,但难以预测患者肿瘤细胞对其的敏感性。为此,科学家们研究了许多方法来克服这一困难,如克隆形成法、染料排除法和放射性同位素掺入法。但由于克隆形成法需时长,仅能检测单个细胞药敏;染料排除法费时,且易受主观因素影响;而放射性同位素掺入法需较好的仪器设备,并受同位素照射损伤,因而它们都难以达到简单、快速、易于推广和自动化的要求。而最近发现的 MTT(可被活细胞线粒体代谢形成有色甲臜)法可满足上述要求,并用于新药筛选和急慢性白血
Cytotoxic drug therapy is the main method for the treatment of acute myeloid leukemia (AML), but it is difficult to predict the sensitivity of the patient’s tumor cells. To this end, scientists have studied many methods to overcome this difficulty, such as cloning, dye exclusion, and radioactive isotope incorporation. However, the cloning method takes a long time and can only detect the susceptibility of a single cell; the dye exclusion method is time-consuming and susceptible to subjective factors; and the radioisotope incorporation method requires better instruments and equipment, and is damaged by isotope irradiation, so they are all It is difficult to achieve the requirements of simplicity, speed, ease of promotion and automation. The recently discovered MTT (which can be metabolized by living cell mitochondria to form colored formazan) can meet the above requirements and be used for new drug screening and acute and chronic white blood.